James and Brian will provide a look at how the EO establishes a policy of decreasing reliance on foreign manufacturers for certain medical products (including pharmaceuticals) through a series of changes to procurement priorities. James will focus on those changes that may result in significant limits to current manufacturing processes outside the U.S. for pharmaceutical manufacturers and distributors as well as the potential impact of changes awardee selection requirements. Brian will address the broad scope of the unfunded mandate to the U.S. Food & Drug Administration under the EO, the requirements related to areas not traditionally regulated by the agency as well as impact of uncertainty regarding the resulting changes for the pharmaceutical industry.
If your pricing does not match the membership level, please contact Michael Hanafin at email@example.com.
Keystone: Unlimited Complimentary
Executive/Strategic Partner: Unlimited Complimentary
Premier: Unlimited Complimentary
Government: Unlimited Complimentary